Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 9/20 | 0.63 |
| ▸ | SCNN1A | P37088 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | GLA | P06280 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamil SCHEMBL5433990 | 1.00 | PLAU (0.63) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| Benzamil SCHEMBL4242779 | 1.00 | PLAU (0.63) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| Benzamil SCHEMBL9464171 | 0.99 | PLAU (0.64) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| SCHEMBL11615365 | 0.94 | PLAU (0.59) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| SCHEMBL10028719 | 0.85 | SCNN1A (0.61) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| 3',4' Dichlorobenzamil SCHEMBL14504158 | 0.85 | HSD17B10 (0.60) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| SCHEMBL5065784 | 0.83 | KCNH2 (0.51) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| SCHEMBL5014171 | 0.82 | SCNN1A (0.52) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| Phenamil SCHEMBL14504131 | 0.81 | PLAU (0.58) | PLAUSCNN1AALDH1A1KDM4EGLA | |
| Phenamil SCHEMBL14973571 | 0.81 | PLAU (0.58) | PLAUSCNN1AALDH1A1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1958 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057876-A1 | METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS | GOLDRED NANOBIOTECH CO., LTD. (TW) | 2025-02-20 | — | — | US | claimed |
| US-20250009739-A1 | METHOD OF TREATING A SKIN DISORDER | PHAMRI NORDEN AB (SE) | 2025-01-09 | — | — | US | claimed |
| US-20250002463-A1 | NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE | PSOMRI HOLDING AB (SE) | 2025-01-02 | — | — | US | claimed |
| EP-4408826-A1 | NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE | Psomri Holding AB (SE) | 2024-08-07 | — | — | EP | claimed |
| US-20240180955-A1 | FIBER SUPPLEMENTATION PROTECTS FROM ANTIBIOTIC-INDUCED GUT MICROBIOME DYSBIOSIS BY MODULATING REDOX METABOLISM | BROWN UNIVERSITY | 2024-06-06 | — | — | US | claimed |
| EP-4281075-A2 | METHOD OF TREATING A SKIN DISORDER BY ADMINISTERING AN AMILORIDE DERIVATIVE | Pharmi Norden AB (SE) | 2023-11-29 | — | — | EP | claimed |
| US-11826366-B2 | Composition and methods for preventing or reducing the incidence of transient ischemic attacks | MOREHOUSE SCHOOL OF MEDICINE (US) | 2023-11-28 | — | — | US | claimed |
| US-11819535-B2 | Composition and methods for regulating extracellular matrix accumulation | UNIVERSITY HEALTH NETWORK (CA) | 2023-11-21 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| WO-2023066893-A1 | AMILORIDE DERIVATIVES FOR TREATING INFLAMMATION IN THE INTESTINES | PHAMRI NORDEN AB (SE) | 2023-04-27 | — | — | WO | claimed |
| EP-0778768-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA | Euroceltique S.A. (LU) | 1997-06-18 | — | — | EP | claimed |
| US-5635160-A | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-06-03 | — | — | US | claimed |
| US-5628984-A | Method of detecting lung disease | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-05-13 | — | — | US | claimed |
| WO-1997005195-A1 | METHOD OF DETECTING LUNG DISEASE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-13 | — | — | WO | claimed |
| WO-1996041616-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA | EURO-CELTIQUE, S.A. (LU) | 1996-12-27 | — | — | WO | claimed |
| WO-1996040059-A1 | DINUCLEOTIDES USEFUL FOR THE TREATMENT OF LUNG DISEASE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996018385-A1 | METHODS OF TREATING LUNG DISEASE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-06-20 | — | — | WO | claimed |
| WO-1996013158-A2 | PROLONGED PRESERVATION OF BLOOD PLATELETS | LIFECELL CORPORATION (US) | 1996-05-09 | — | — | WO | claimed |
| EP-0451130-A2 | Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization | CELTRIX PHARMACEUTICALS, INC. (US) | 1991-10-09 | — | — | EP | claimed |
| US-4894376-A | Methods of treating diseases characterized by hyperexcitability of neurons | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1990-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009739-A1 | METHOD OF TREATING A SKIN DISORDER | CUTA, KRT18, ASAH2 | PLAU 216/4885SCNN1A 255/4885ALDH1A1 345/4885 |
| US-20250002463-A1 | NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE | ASIC1, PPA1, ASIC3 | PLAU 1690/4885SCNN1A 175/4885ALDH1A1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.